Jänne PA - Search Results

1

An unbiased in vitro screen for activating epidermal growth factor receptor mutations.

Chakroborty D, Kurppa KJ, Paatero I, Ojala VK, Koivu M, Tamirat MZ, Koivunen JP, Jänne PA, Johnson MS, Elo LL, Elenius K. Chakroborty D, et al. Among authors: janne pa. J Biol Chem. 2019 Jun 14;294(24):9377-9389. doi: 10.1074/jbc.RA118.006336. Epub 2019 Apr 5. J Biol Chem. 2019. PMID: 30952700 Free PMC article.

2

Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.

Jänne PA, Taffaro ML, Salgia R, Johnson BE. Jänne PA, et al. Cancer Res. 2002 Sep 15;62(18):5242-7. Cancer Res. 2002. PMID: 12234991

3

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. Paez JG, et al. Among authors: janne pa. Science. 2004 Jun 4;304(5676):1497-500. doi: 10.1126/science.1099314. Epub 2004 Apr 29. Science. 2004. PMID: 15118125

4

Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology.

Jänne PA, Engelman JA, Johnson BE. Jänne PA, et al. J Clin Oncol. 2005 May 10;23(14):3227-34. doi: 10.1200/JCO.2005.09.985. J Clin Oncol. 2005. PMID: 15886310 Review.

5

Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.

Mukohara T, Engelman JA, Hanna NH, Yeap BY, Kobayashi S, Lindeman N, Halmos B, Pearlberg J, Tsuchihashi Z, Cantley LC, Tenen DG, Johnson BE, Jänne PA. Mukohara T, et al. Among authors: janne pa. J Natl Cancer Inst. 2005 Aug 17;97(16):1185-94. doi: 10.1093/jnci/dji238. J Natl Cancer Inst. 2005. PMID: 16106023

6

Epidermal growth factor receptor mutations in patients with non-small cell lung cancer.

Johnson BE, Jänne PA. Johnson BE, et al. Among authors: janne pa. Cancer Res. 2005 Sep 1;65(17):7525-9. doi: 10.1158/0008-5472.CAN-05-1257. Cancer Res. 2005. PMID: 16140912 Review.

7

Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression.

Jiang J, Greulich H, Jänne PA, Sellers WR, Meyerson M, Griffin JD. Jiang J, et al. Among authors: janne pa. Cancer Res. 2005 Oct 1;65(19):8968-74. doi: 10.1158/0008-5472.CAN-05-1829. Cancer Res. 2005. PMID: 16204070

8

Ongoing first-line studies of epidermal growth factor receptor tyrosine kinase inhibitors in select patient populations.

Jänne PA. Jänne PA. Semin Oncol. 2005 Dec;32(6 Suppl 10):S9-15. doi: 10.1053/j.seminoncol.2005.10.004. Semin Oncol. 2005. PMID: 16459174 Review.

9

A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening.

Jänne PA, Borras AM, Kuang Y, Rogers AM, Joshi VA, Liyanage H, Lindeman N, Lee JC, Halmos B, Maher EA, Distel RJ, Meyerson M, Johnson BE. Jänne PA, et al. Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):751-8. doi: 10.1158/1078-0432.CCR-05-2047. Clin Cancer Res. 2006. PMID: 16467085

10

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.

Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ, Meyerson M, Johnson BE, Jänne PA. Jackman DM, et al. Among authors: janne pa. Clin Cancer Res. 2006 Jul 1;12(13):3908-14. doi: 10.1158/1078-0432.CCR-06-0462. Clin Cancer Res. 2006. PMID: 16818686

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

474 results

Search Page